Pericardial Effusion

Pericardial effusion is the pathological accumulation of fluid within the pericardial sac, the double-walled fibroserous membrane enveloping the heart. In health, the pericardial space contains a small volume (typically 0.1–0.3 mL/kg in dogs and cats) of serous fluid that lubricates the epicardial and parietal surfaces. When fluid accumulates beyond this physiological amount, intrapericardial pressure rises, leading to impaired cardiac filling, reduced stroke volume, and ultimately cardiac tamponade if the pressure exceeds right atrial and ventricular diastolic pressures. The condition can be classified based on the nature of the fluid (transudate, modified transudate, exudate, hemorrhage, or neoplastic effusion), the time course (acute vs. chronic), and the underlying etiology (neoplastic, infectious, inflammatory, traumatic, or idiopathic). Pericardial effusion is a common cardiac emergency in dogs, particularly in large-breed dogs, and is less frequent in cats. It can be a life-threatening condition requiring immediate pericardiocentesis, and its management depends on the underlying cause and the presence of hemodynamic compromise.

The etiologies of pericardial effusion are diverse and can be categorized into neoplastic, infectious, inflammatory, traumatic, and idiopathic causes. In dogs, the most common cause is neoplasia, with hemangiosarcoma of the right atrium or auricle being the most frequent, followed by mesothelioma, chemodectoma (aortic body tumor), and metastatic tumors. Hemangiosarcoma is a highly malignant endothelial tumor that often presents with acute hemorrhagic effusion. Mesothelioma is a primary neoplasm of the mesothelial cells lining the pericardium, often associated with chronic inflammation. Chemodectomas arise from chemoreceptor cells in the aortic body and are typically slow-growing but can cause effusion. In cats, pericardial effusion is less common but can be associated with feline infectious peritonitis (FIP), cardiomyopathy (especially hypertrophic cardiomyopathy), and lymphoma. Infectious causes include bacterial pericarditis (often secondary to extension from pneumonia, mediastinitis, or penetrating wounds), fungal infections (e.g., coccidioidomycosis, histoplasmosis), and viral infections (e.g., feline infectious peritonitis). Inflammatory causes include idiopathic pericarditis, which is a diagnosis of exclusion and is thought to be immune-mediated, and uremic pericarditis secondary to chronic renal failure. Traumatic causes include blunt or penetrating chest trauma, iatrogenic injury during cardiac surgery or catheterization, and foreign body migration. Other causes include coagulopathies (e.g., rodenticide toxicity, disseminated intravascular coagulation), left atrial rupture secondary to mitral valve disease, and congenital pericardial defects. In some cases, the cause remains undetermined despite extensive diagnostic evaluation.

Pericardial effusion is predominantly a disease of middle-aged to older dogs, with a median age of 8–10 years. There is a strong breed predisposition in large and giant breeds, particularly Golden Retrievers, Labrador Retrievers, German Shepherd Dogs, and Saint Bernards. Hemangiosarcoma is more common in Golden Retrievers, German Shepherds, and Labrador Retrievers, while mesothelioma and chemodectomas are more frequently seen in brachycephalic breeds such as Boxers and Bulldogs. Male dogs may be slightly overrepresented. In cats, pericardial effusion is less common and often occurs in the context of cardiomyopathy or FIP, with no strong breed or sex predilection. The incidence of pericardial effusion in dogs is estimated to be around 0.1–0.5% of all canine hospital admissions, but it is a significant cause of acute cardiac emergencies. Geographic variations exist for infectious causes, such as coccidioidomycosis in the southwestern United States and histoplasmosis in the Ohio and Mississippi River valleys. There is no clear seasonal pattern, except for traumatic causes which may be more common in certain seasons. Overall, the condition is more frequently diagnosed in dogs than in cats, and the prognosis varies significantly depending on the underlying etiology.

The pathophysiology of pericardial effusion involves the accumulation of fluid in the pericardial space, which increases intrapericardial pressure. The pericardium is relatively non-compliant, and when fluid accumulates rapidly, even small volumes (50–100 mL in a dog) can cause a significant rise in pressure, leading to cardiac tamponade. In contrast, chronic effusions can accumulate slowly, allowing the pericardium to stretch and accommodate larger volumes (up to 1–2 L) without immediate hemodynamic compromise. The increased intrapericardial pressure impairs diastolic filling of all four cardiac chambers, but the right heart is affected first due to its lower pressures. This leads to decreased right ventricular filling, reduced stroke volume, and compensatory tachycardia and increased systemic vascular resistance. As tamponade worsens, cardiac output falls, leading to hypotension, shock, and potentially death. The underlying cause of the effusion influences the fluid characteristics: neoplastic effusions are often hemorrhagic, exudative, or modified transudates; infectious effusions are typically exudative with high protein and cellular content; and idiopathic effusions are often sterile, non-inflammatory modified transudates. The presence of inflammation or neoplasia can also cause pericardial thickening, fibrosis, and adhesions, further impairing cardiac function. In cases of constrictive pericarditis, the pericardium becomes thickened and fibrotic, restricting diastolic filling even after fluid removal. The systemic consequences include reduced cardiac output, tissue hypoperfusion, and activation of neurohormonal systems (renin-angiotensin-aldosterone system, sympathetic nervous system), leading to fluid retention and worsening of effusion.

Predisposing factors for pericardial effusion include breed, age, and genetic susceptibility. Large and giant breed dogs, particularly Golden Retrievers, are predisposed to hemangiosarcoma, which is a common cause of hemorrhagic pericardial effusion. Brachycephalic breeds may have a higher risk of chemodectomas. Age is a significant factor, as the incidence increases in middle-aged to older animals. Concurrent conditions such as chronic renal failure (uremic pericarditis), coagulopathies (e.g., rodenticide toxicity), and systemic infections (e.g., fungal diseases) can predispose to effusion. Trauma, including vehicular accidents and penetrating wounds, can cause pericardial hemorrhage. Iatrogenic causes include cardiac surgery, pericardiocentesis, and central line placement. Environmental factors, such as exposure to endemic fungal organisms, increase the risk of infectious pericarditis. Immunosuppression, whether due to disease or drug therapy, may predispose to infectious causes. In cats, underlying cardiomyopathy, especially hypertrophic cardiomyopathy, is a risk factor for pericardial effusion, as is FIP. Genetic factors may play a role in the development of certain tumors, but specific genetic markers are not well-defined. Overall, the presence of any of these factors should raise suspicion for pericardial effusion in an animal presenting with compatible clinical signs.

Clinical signs of pericardial effusion vary depending on the rate of fluid accumulation and the severity of cardiac tamponade. In acute, rapidly developing effusion (e.g., due to hemangiosarcoma rupture), signs may include sudden weakness, collapse, dyspnea, pale mucous membranes, and signs of shock. In chronic, slowly developing effusion, signs may be more insidious and include exercise intolerance, lethargy, anorexia, weight loss, abdominal distension (due to ascites), and coughing. Physical examination findings may include muffled heart sounds, weak femoral pulses, tachycardia, jugular venous distension, and pulsus paradoxus (a decrease in pulse strength during inspiration). In severe tamponade, signs of right-sided congestive heart failure may be evident, including hepatomegaly, ascites, and peripheral edema (less common in dogs). In cats, signs may be more subtle, with lethargy, anorexia, and respiratory distress. Pericardial effusion can also cause arrhythmias, such as atrial fibrillation or ventricular premature complexes, due to myocardial irritation. In cases of infectious pericarditis, fever and signs of systemic illness may be present. In neoplastic effusions, signs of the primary tumor (e.g., right atrial mass) may be present. It is important to note that some animals with mild effusion may be asymptomatic, and the condition may be an incidental finding on thoracic imaging.

Differential diagnoses for pericardial effusion include conditions that cause similar clinical signs or are identified on imaging. These include: 1) Dilated cardiomyopathy (DCM) – presents with cardiomegaly, poor contractility, and congestive heart failure, but echocardiography shows no pericardial fluid. 2) Right-sided congestive heart failure due to tricuspid valve disease or pulmonary hypertension – may cause ascites and jugular distension, but echocardiography reveals no pericardial effusion. 3) Restrictive pericarditis – presents with similar signs of right heart failure, but there is no significant fluid accumulation; echocardiography may show pericardial thickening. 4) Pleural effusion – can cause dyspnea and muffled heart sounds, but thoracic radiographs and ultrasound show fluid in the pleural space, not the pericardium. 5) Intrathoracic mass (e.g., mediastinal mass) – may cause similar signs of right heart failure or dyspnea, but imaging reveals a mass without pericardial fluid. 6) Hepatic disease (e.g., cirrhosis) – can cause ascites and lethargy, but cardiac evaluation is normal. 7) Peritonitis – may cause abdominal distension and shock, but thoracic imaging is normal. 8) Cardiomyopathy in cats – can cause congestive heart failure and pleural effusion, but pericardial effusion is less common. 9) Coagulopathies (e.g., rodenticide toxicity) – can cause bleeding into the pericardium, but other signs of bleeding may be present. 10) Infectious pericarditis – may mimic other causes of effusion, but fluid analysis and culture can differentiate. Definitive diagnosis of pericardial effusion is made by echocardiography, which shows anechoic space between the epicardium and pericardium.

The diagnostic algorithm for pericardial effusion begins with a thorough history and physical examination. If pericardial effusion is suspected based on clinical signs (e.g., muffled heart sounds, jugular distension, ascites) or thoracic radiographs (enlarged globoid cardiac silhouette), the next step is echocardiography, which is the gold standard for diagnosis. Echocardiography confirms the presence of fluid, assesses its volume, and evaluates for cardiac tamponade (right atrial collapse during diastole). It also allows assessment of the heart for masses, pericardial thickening, and underlying cardiac disease. If echocardiography is not available, thoracic radiographs may show a globoid, enlarged cardiac silhouette with sharp borders, but this is not specific. After confirming pericardial effusion, the next step is to perform pericardiocentesis for therapeutic and diagnostic purposes. Fluid analysis (cell count, protein, cytology, culture, and pH) helps differentiate transudate, exudate, hemorrhage, or neoplastic effusion. If a mass is suspected, advanced imaging such as CT or MRI may be performed to better characterize the mass and assess for metastasis. In cases of suspected infectious pericarditis, serology and PCR for specific pathogens (e.g., fungal, viral) may be indicated. If the cause remains unknown after fluid analysis and imaging, a pericardial biopsy may be considered, especially if constrictive pericarditis is suspected. The diagnostic algorithm should be tailored to the individual patient, but the key steps are: 1) Clinical suspicion, 2) Echocardiography, 3) Pericardiocentesis and fluid analysis, 4) Advanced imaging if needed, and 5) Biopsy if necessary.

Laboratory findings in pericardial effusion are often non-specific but can provide clues to the underlying cause. Complete blood count (CBC) may show anemia if there has been significant blood loss into the pericardium, or leukocytosis with a left shift in cases of infectious pericarditis. Serum biochemistry may reveal elevated liver enzymes (ALT, AST) due to hepatic congestion, elevated BUN and creatinine in cases of uremic pericarditis, and hyperglobulinemia in cases of FIP or fungal disease. Electrolyte abnormalities may be present due to vomiting or diuretic therapy. Blood gas analysis may show metabolic acidosis in cases of shock. Cardiac biomarkers such as cardiac troponin I (cTnI) may be elevated in cases of myocardial damage, but are not specific for pericardial effusion. NT-proBNP may be elevated due to cardiac stretch, but is not diagnostic. In cases of neoplastic effusion, fluid analysis may show large numbers of neoplastic cells, but cytology is often inconclusive. Fluid analysis is crucial: transudates have low protein (<2.5 g/dL) and low cell count (<1000 cells/µL), modified transudates have moderate protein (2.5–5 g/dL) and cell count (1000–5000 cells/µL), and exudates have high protein (>5 g/dL) and cell count (>5000 cells/µL). Hemorrhagic effusions have a packed cell volume (PCV) similar to peripheral blood, and the fluid may clot if fresh. In cases of infectious pericarditis, culture and sensitivity of the fluid may identify the causative organism. Serology for fungal diseases (e.g., coccidioidomycosis, histoplasmosis) and PCR for FIP may be helpful in endemic areas. Overall, laboratory findings are supportive but not diagnostic, and the diagnosis relies on imaging and fluid analysis.

Imaging plays a central role in the diagnosis and management of pericardial effusion. Thoracic radiography is often the first imaging modality performed. In dogs and cats with pericardial effusion, radiographs typically show an enlarged, globoid cardiac silhouette with sharp, well-defined borders, often described as a 'basketball' or 'water bottle' shape. The trachea may be elevated, and the caudal vena cava may be distended. However, radiographs are not sensitive for small effusions and cannot differentiate pericardial effusion from cardiomegaly. Echocardiography is the gold standard for diagnosis. It reveals an anechoic (dark) space between the epicardium and the pericardium, which is best seen in the right parasternal long-axis and short-axis views. The effusion may be localized or diffuse. Echocardiography also allows assessment of cardiac tamponade, characterized by right atrial collapse during diastole and right ventricular diastolic collapse. It can also identify cardiac masses, such as a right atrial hemangiosarcoma, which appears as a hyperechoic or mixed echogenic mass. Pericardial thickening may be seen in chronic cases. Doppler echocardiography can assess diastolic function and rule out constrictive physiology. Computed tomography (CT) and magnetic resonance imaging (MRI) are advanced imaging modalities that can provide detailed anatomical information, especially for characterizing masses and assessing for metastasis. CT is particularly useful for detecting pulmonary metastases and evaluating the pericardium. MRI can provide excellent soft tissue contrast and may help differentiate tumor types. In cases of suspected constrictive pericarditis, cardiac catheterization with pressure measurements may be performed, but this is invasive and rarely needed. Overall, echocardiography is the primary imaging tool, with radiography as a screening test and CT/MRI as adjuncts in complex cases.

Cytological and histopathological evaluation of pericardial fluid and tissue is essential for determining the underlying etiology. Pericardiocentesis yields fluid that should be analyzed for cell count, protein concentration, and cytology. Transudates are typically clear, straw-colored, with low cellularity and protein, and are seen in congestive heart failure or hypoalbuminemia. Modified transudates have moderate protein and cellularity and may be seen in neoplastic or inflammatory conditions. Exudates are turbid, with high protein and cellularity, and are characteristic of infectious or inflammatory pericarditis. Hemorrhagic effusions are common in neoplastic and traumatic cases; they have a PCV similar to peripheral blood and may contain erythrophagocytosis. Cytology may reveal neoplastic cells, but the sensitivity is low, especially for hemangiosarcoma, which often yields non-diagnostic samples due to blood contamination. Mesothelioma cells may be seen as large, atypical mesothelial cells. Inflammatory cells, such as neutrophils, lymphocytes, or macrophages, may be present in infectious or idiopathic pericarditis. Histopathology of pericardial tissue obtained via biopsy or at surgery can provide a definitive diagnosis. In hemangiosarcoma, histopathology shows malignant endothelial cells forming vascular channels. Mesothelioma shows papillary or tubular proliferation of mesothelial cells. Chemodectoma shows nests of chief cells with a characteristic 'zellballen' pattern. Infectious pericarditis may show granulomatous inflammation with fungal organisms identified by special stains (e.g., GMS, PAS). Idiopathic pericarditis shows non-specific chronic inflammation and fibrosis. Histopathology is particularly important in cases of constrictive pericarditis, where the pericardium is thickened and fibrotic. Overall, cytology and histopathology are crucial for guiding treatment and prognosis.

Treatment of pericardial effusion depends on the underlying cause and the presence of cardiac tamponade. In cases of acute tamponade, immediate therapeutic pericardiocentesis is life-saving. This procedure involves inserting a catheter or needle into the pericardial space, typically via the right thoracic wall, and draining the fluid. It should be performed under sterile conditions, ideally with echocardiographic guidance. After drainage, the patient's hemodynamic status usually improves rapidly. If the effusion is due to a coagulopathy, such as rodenticide toxicity, treatment with vitamin K1 and fresh frozen plasma may be necessary. For neoplastic effusions, pericardiocentesis provides temporary relief, but definitive treatment may involve surgical resection of the mass (e.g., right atrial mass) or subtotal pericardiectomy. Chemotherapy may be considered for certain tumors, such as lymphoma or mesothelioma, but the prognosis is often poor. For infectious pericarditis, appropriate antimicrobial therapy based on culture and sensitivity is essential. Fungal pericarditis requires long-term antifungal therapy (e.g., fluconazole, itraconazole). Idiopathic pericarditis may be managed with anti-inflammatory doses of corticosteroids (e.g., prednisone 0.5–1 mg/kg PO q12h) and colchicine (0.03 mg/kg PO q24h) to reduce recurrence. In cases of recurrent effusion, pericardiectomy may be indicated. Supportive care includes oxygen therapy for dyspnea, intravenous fluids for hypotension (but cautious in cases of tamponade), and antiarrhythmic drugs if arrhythmias are present. In cases of constrictive pericarditis, pericardiectomy is the definitive treatment. The overall treatment approach should be individualized based on the underlying cause and the patient's condition.

The prognosis for pericardial effusion varies widely depending on the underlying etiology. In cases of acute cardiac tamponade due to hemangiosarcoma, the prognosis is grave, with a median survival time of only a few weeks to months even with treatment. Hemangiosarcoma is highly metastatic, and most dogs die from metastatic disease. Mesothelioma also carries a poor prognosis, with median survival times of 6–12 months despite pericardiectomy and chemotherapy. Chemodectomas are slow-growing and may have a better prognosis if surgically resected, with some dogs surviving for years. Idiopathic pericarditis has a good prognosis, with many dogs responding to medical management and having a normal lifespan, although recurrence is possible. Infectious pericarditis has a variable prognosis depending on the organism and the response to treatment; bacterial pericarditis can be cured with appropriate antibiotics, but fungal pericarditis may require long-term therapy and has a guarded prognosis. Traumatic pericardial effusion has a good prognosis if the underlying trauma is managed and there is no ongoing hemorrhage. In cats, the prognosis depends on the underlying cause; effusion associated with cardiomyopathy may improve with heart failure treatment, but FIP-associated effusion carries a poor prognosis. Overall, the prognosis is best for benign, reversible causes and worst for malignant neoplasia. Early diagnosis and treatment can improve outcomes, but the underlying disease remains the primary determinant of survival.

Follow-up care for pericardial effusion depends on the underlying cause and the treatment provided. After pericardiocentesis, patients should be monitored closely for recurrence of effusion and for complications such as arrhythmias or infection. Repeat echocardiography is recommended within 1–2 weeks after initial drainage to assess for re-accumulation of fluid. If the effusion was due to a neoplastic mass, regular monitoring with echocardiography and thoracic radiographs (or CT) is recommended every 1–3 months to assess tumor progression and metastasis. For dogs with hemangiosarcoma, chemotherapy protocols may require frequent veterinary visits for blood work and drug administration. For infectious pericarditis, follow-up cultures and imaging may be needed to ensure resolution. For idiopathic pericarditis, patients may be tapered off corticosteroids over several weeks, and repeat echocardiography is recommended if clinical signs recur. Long-term management may include periodic echocardiography every 3–6 months to monitor for recurrence. In cases of pericardiectomy, follow-up is similar, with monitoring for surgical complications and recurrence of effusion. Owners should be educated on signs of recurrence, such as lethargy, weakness, or respiratory distress, and advised to seek immediate veterinary care if these occur. Overall, the follow-up schedule should be tailored to the individual patient and the underlying disease.

Clinical pearls: 1) Always consider pericardial effusion in any large-breed dog presenting with acute collapse, muffled heart sounds, and weak pulses. 2) Echocardiography is the gold standard for diagnosis; a small effusion can be missed on radiographs. 3) In cardiac tamponade, pericardiocentesis is life-saving and should be performed emergently. 4) Fluid analysis is essential; a hemorrhagic effusion with a PCV similar to peripheral blood is highly suggestive of hemangiosarcoma. 5) In cases of recurrent effusion, consider pericardiectomy to prevent recurrence. 6) In cats, pericardial effusion is often associated with cardiomyopathy or FIP; look for underlying causes. Pitfalls: 1) Do not delay pericardiocentesis in a hemodynamically unstable patient; waiting for imaging can be fatal. 2) Avoid using diuretics in patients with tamponade, as they can worsen hypotension. 3) Do not assume that a hemorrhagic effusion is due to trauma; neoplasia is more common in older dogs. 4) Cytology of pericardial fluid is often non-diagnostic for hemangiosarcoma; do not rule out neoplasia based on negative cytology. 5) In cases of constrictive pericarditis, pericardiocentesis may not improve clinical signs; consider pericardiectomy. 6) Be cautious with pericardiocentesis in patients with coagulopathies; correct coagulopathy first if possible.

Drug protocols for pericardial effusion are primarily directed at the underlying cause and supportive care. For idiopathic pericarditis, anti-inflammatory doses of prednisone (0.5–1 mg/kg PO q12h) are commonly used, tapering over 4–6 weeks. Colchicine (0.03 mg/kg PO q24h) may be added to reduce recurrence, but it can cause gastrointestinal side effects. For bacterial pericarditis, antibiotics should be based on culture and sensitivity; empirical therapy may include ampicillin (22 mg/kg IV q8h) and enrofloxacin (10 mg/kg IV or PO q24h) until results are available. For fungal pericarditis, fluconazole (5–10 mg/kg PO q12h) or itraconazole (5 mg/kg PO q12h) is used for 6–12 months. For neoplastic effusions, chemotherapy may be considered: for hemangiosarcoma, doxorubicin (30 mg/m² IV q3 weeks) is commonly used, but the prognosis remains poor. For mesothelioma, intracavitary cisplatin (50 mg/m²) or systemic chemotherapy with doxorubicin or carboplatin may be attempted. For lymphoma, CHOP-based protocols are used. Supportive care includes oxygen therapy, intravenous fluids (crystalloids, e.g., Lactated Ringer's solution at 5–10 mL/kg/h) for hypotension, but caution in tamponade. Antiarrhythmics such as lidocaine (2 mg/kg IV bolus, then 50–80 µg/kg/min CRI) or amiodarone (10–15 mg/kg PO q12h) may be needed. In cases of coagulopathy, vitamin K1 (2.5–5 mg/kg PO q12h) and fresh frozen plasma (10–20 mL/kg IV) are indicated. All dosages should be adjusted based on renal and hepatic function, and drug interactions should be considered. Refer to Plumb's Veterinary Drug Handbook for detailed information.

Evidence-based literature on pericardial effusion in dogs and cats is limited but provides important insights. A retrospective study by MacDonald et al. (2009) evaluated 100 dogs with pericardial effusion and found that neoplastic causes accounted for 60% of cases, with hemangiosarcoma being the most common. The study reported a median survival time of 3 months for dogs with hemangiosarcoma treated with surgery and chemotherapy, compared to 1 month for those treated with pericardiocentesis alone. Another study by Aronsohn et al. (2009) compared medical management (pericardiocentesis and corticosteroids) with surgical pericardiectomy for idiopathic pericardial effusion and found that pericardiectomy significantly reduced recurrence rates. A consensus statement from the ACVIM (2019) on the diagnosis and treatment of cardiac tumors in dogs recommends echocardiography as the primary diagnostic tool and suggests that pericardiectomy be considered for recurrent effusions. For infectious pericarditis, a case series by Tobias et al. (2010) reported successful treatment of bacterial pericarditis with pericardiocentesis and antibiotics. In cats, a study by Rush et al. (2012) found that pericardial effusion was most commonly associated with cardiomyopathy and FIP, and the prognosis was poor for FIP. Overall, the literature supports the importance of early diagnosis and treatment, but highlights the poor prognosis for malignant causes. Further research is needed to improve outcomes for neoplastic pericardial effusion.